VANCOMYCIN HCL
VANCOMYCIN INTRAVENOUS · CLOSTRIDIOIDES DIFFICILE INFECTION ·+18
AVENACY, INC
Drug class
Vancomycin Intravenous
Rather than constituting an independent therapeutic drug class, "vancomycin intravenous" represents a specific route-based formulation and administration method of vancomycin, an antimicrobial belonging to the glycopeptide antibacterial class. Read more about Vancomycin Intravenous
38 drugs in this class 30 manufacturers
Drugs in Vancomycin Intravenous
VANCOMYCIN HCL
VANCOMYCIN INTRAVENOUS · CLOSTRIDIOIDES DIFFICILE INFECTION ·+18
MEDIMETRIKS-EUR
Filter & compare in the drug finder →
Opens the drug finder with Vancomycin Intravenous preselected. Add indication or manufacturer filters there.
Rather than constituting an independent therapeutic drug class, "vancomycin intravenous" represents a specific route-based formulation and administration method of vancomycin, an antimicrobial belonging to the glycopeptide antibacterial class.
It exerts bactericidal action by inhibiting bacterial cell wall synthesis through high-affinity binding to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors.
Administered parenterally for systemic bioavailability, intravenous vancomycin serves as a first-line therapy for severe or life-threatening Gram-positive infections, particularly those caused by methicillin-resistant *Staphylococcus aureus* (MRSA).
Its primary therapeutic indications include bacteremia, infective endocarditis, osteomyelitis, complicated skin and soft tissue infections, and lower respiratory tract infections.
-
nih.gov
Rather than constituting an independent therapeutic drug class, "vancomycin intravenous" represents a specific route-based formulation and administration method of vancomycin, an antimicrobial belonging to the glycopeptide antibacterial class It exerts bactericidal action by inhibiting bacterial cell wall synthesis through high-affinity binding to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors Administered parenterally for systemic bioavailability, intravenous vancomycin s...
-
fda.gov
It exerts bactericidal action by inhibiting bacterial cell wall synthesis through high-affinity binding to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors Administered parenterally for systemic bioavailability, intravenous vancomycin serves as a first-line therapy for severe or life-threatening Gram-positive infections, particularly those caused by methicillin-resistant *Staphylococcus aureus* (MRSA) Its primary therapeutic indications include bacteremia, infective endocard...
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.